Aslan Pharma In-licenses China Rights to BMS Cancer Drug

Aslan Pharmaceuticals, a pharmaceutical startup based in Singapore, has entered a strategic partnership with Bristol-Myers Squibb. Aslan will fund development of a BMS oncology candidate, BMS-777607, following a pre-agreed BMS program. BMS-777607 is a small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors. The compound is expected to target gastric and lung cancer. More details.... Stock Symbol: (NYSE: BMY)